Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 25079365)

1.

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.

Morton AC, Rothman AM, Greenwood JP, Gunn J, Chase A, Clarke B, Hall AS, Fox K, Foley C, Banya W, Wang D, Flather MD, Crossman DC.

Eur Heart J. 2015 Feb 7;36(6):377-84. doi: 10.1093/eurheartj/ehu272. Epub 2014 Jul 30.

2.

Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study).

Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, Lucking AJ, Flather MD, Lees B, Foley CE.

Trials. 2008 Feb 25;9:8. doi: 10.1186/1745-6215-9-8.

3.

Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes.

Ray KK, Camp NJ, Bennett CE, Francis SE, Crossman DC.

Clin Sci (Lond). 2002 Sep;103(3):303-10.

PMID:
12193156
4.

Time course changes of cystatin C and inflammatory and biochemical markers in non-ST-elevation acute coronary syndromes.

De Servi S, Mariani G, Piatti L, Leoncini M, Rubartelli P, Pitì A, Curello S, Galdangelo F, Vandoni P, Rossetti E, Mariani M, Boschetti E, Re G, Loznicker M.

J Cardiovasc Med (Hagerstown). 2014 Jan;15(1):42-7. doi: 10.2459/JCM.0b013e328365a275.

PMID:
24492354
6.

Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction.

Patti G, D'Ambrosio A, Mega S, Giorgi G, Zardi EM, Zardi DM, Dicuonzo G, Dobrina A, Di Sciascio G.

J Am Coll Cardiol. 2004 Jan 7;43(1):35-8.

7.

Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes.

Yan HB, Song L, Liu R, Zhao HJ, Wang SP, Chi YP, Zheng B, Li WZ, Liu C, Zhou P.

Chin Med J (Engl). 2011 Mar;124(6):879-86.

PMID:
21518596
8.

The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.

Bresnihan B.

Semin Arthritis Rheum. 2001 Apr;30(5 Suppl 2):17-20.

PMID:
11357167
9.
10.

In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.

Giansante C, Fiotti N, Di Chiara A, Altamura N, Wasserman S, Fioretti P, Guarnieri G.

J Cardiovasc Med (Hagerstown). 2007 Aug;8(8):602-7.

PMID:
17667031
11.

Gamma-glutamyltransferase in acute coronary syndrome patients without ST elevation and its association with stenotic lesion and cardiac events.

Dogan A, Icli A, Aksoy F, Varol E, Erdogan D, Ozaydin M, Kocyigit S.

Coron Artery Dis. 2012 Jan;23(1):39-44. doi: 10.1097/MCA.0b013e32834e4ed0.

PMID:
22107801
12.

Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.

Wang Z, Dai H, Xing M, Yu Z, Lin X, Wang S, Zhang J, Hou F, Ma Y, Ren Y, Tan K, Wang Y, Ge Z.

J Cardiovasc Pharmacol Ther. 2013 Jul;18(4):327-33. doi: 10.1177/1074248412474346. Epub 2013 Jan 29.

PMID:
23364255
13.

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.

Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N.

Health Technol Assess. 2009 Jun;13(31):iii-iv, ix-xi, 1-77. doi: 10.3310/hta13310. Review.

14.

Plasma granzyme B in ST elevation myocardial infarction versus non-ST elevation acute coronary syndrome: comparisons with IL-18 and fractalkine.

El-Mesallamy HO, Hamdy NM, El-Etriby AK, Wasfey EF.

Mediators Inflamm. 2013;2013:343268. doi: 10.1155/2013/343268. Epub 2013 Nov 6.

15.

Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial).

Ostadal P, Alan D, Vejvoda J, Kukacka J, Macek M, Hajek P, Mates M, Kvapil M, Kettner J, Wiendl M, Aschermann O, Slaby J, Holm F, Telekes P, Horak D, Blasko P, Zemanek D, Veselka J, Cepova J.

Trials. 2010 May 25;11:61. doi: 10.1186/1745-6215-11-61.

16.

Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696].

Ostadal P, Alan D, Hajek P, Vejvoda J, Mates M, Blasko P, Veselka J, Kvapil M, Kettner J, Wiendl M, Aschermann O, Slaby J, Nemecek E, Holm F, Rac M, Macek M, Cepova J.

Curr Control Trials Cardiovasc Med. 2005 Mar 24;6(1):4.

17.

Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254).

Kraus VB, Birmingham J, Stabler TV, Feng S, Taylor DC, Moorman CT 3rd, Garrett WE, Toth AP.

Osteoarthritis Cartilage. 2012 Apr;20(4):271-8. doi: 10.1016/j.joca.2011.12.009. Epub 2012 Jan 10.

18.

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.

Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM; TRILOGY ACS Steering Committee.

Am Heart J. 2010 Jul;160(1):16-22.e1. doi: 10.1016/j.ahj.2010.04.022.

PMID:
20598967
19.

Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).

O'Malley RG, Bonaca MP, Scirica BM, Murphy SA, Jarolim P, Sabatine MS, Braunwald E, Morrow DA.

J Am Coll Cardiol. 2014 Apr 29;63(16):1644-53. doi: 10.1016/j.jacc.2013.12.034. Epub 2014 Feb 13. Erratum in: J Am Coll Cardiol. 2014 Jun 17;63(23):2642.

20.

Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome--RIVIERA trial study design and rationale.

Dominguez-Rodriguez A, Fard SS, Abreu-Gonzalez P, Bosa-Ojeda F, Consuegra-Sanchez L, Jiménez-Sosa A, Grande AS, Kaski JC.

Cardiovasc Drugs Ther. 2009 Jun;23(3):243-7. doi: 10.1007/s10557-009-6164-9. Epub 2009 Feb 20.

PMID:
19229603
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk